Summary
The pharmacokinetics of atracurium, laudanosine and the quaternary alcohol were studied in patients with normal and impaired renal function following intravenous administration of atracurium. Anaesthesia consisted of thiopental, fentanyl, halothane and nitrous oxide in oxygen. Plasma and urine concentrations of the parent compound and its degradation products were measured by high performance liquid chromatography. Renal failure was defined as a creatinine clearance of less than 5 ml/min; it caused no significant differences in the pharmacokinetics of atracurium but did result in a different pharmacokinetic profile of laudanosine, with a 3-fold increase in the mean (± SD) terminal half-life (176 ± 84 and 516 ± 262 minutes for patients with normal and impaired renal function, respectively). Moreover, the half-life of the quaternary alcohol increased from 27.1 ± 8.3 minutes in patients with normal renal function to 42.5 ± 8.3 minutes in those with impaired renal function (mean ± SD). Renal elimination of unchanged atracurium accounted for 11% of the administered dose and at least 27% of the total degradation of atracurium occurred via ester hydrolysis.
The neuromuscular function was monitored by measuring the twitch tension of the adductor pollicis muscle elicited by stimulation of the ulnar nerve at 0.1Hz. The total duration of neuromuscular blockade (51.8 ± 11.5 minutes) and the recovery index (9.6 ± 2.0 minutes) are shortened in patients with impaired renal function, compared with those with normal renal function (64.1 ± 7.2 and 16.7 ± 4.1 minutes, respectively), indicating that sensitivity to the neuromuscular blocking action of atracurium may be altered by renal failure.
Similar content being viewed by others
References
Babel A. Étude comparative de la laudanosine et de la papavérine au point de vue pharmacodynamique. Revue Médicale de la Suisse Romande 19: 657–688, 1899
Bencini AF, Scaf AHJ, Sohn YJ, Meistelman C, Lienhart A. et al. Disposition and urinary excretion of vecuronium bromide in anesthetized patients with normal renal function or renal failure. Anesthesia and Analgesia 65: 245–251, 1986
Boxenbaum AG, Riegelmann S, Elashoff RM. Statistical estimation in pharmacokinetics. Journal of Pharmacokinetics and Biopharmaceutics 2: 123–144, 1974
Chappie DJ, Miller AA, Wheatley PL. Neurological effects of laudanosine in conscious and anaesthetised dogs. Abstract. Anesthesiology 63: A311, 1985
Curtis DR, Duggan AW, Felix D, Johnston GAR. Bicuculline, an antagonist of GABA and synaptic inhibition in the spinal cord of the cat. Brain Research 32: 69–96, 1971
De Bros FM, Lai A, Scott R, De Bros J, Batson AG. et al. Pharmacokinetics and pharmacodynamics of atracurium during isoflurane anesthesia in normal and anephric patients. Anesthesia and Analgesia 65: 743–746, 1986
Fahey MR, Rupp SM, Canfell C, Fisher DM, Miller RD. et al. Effect of renal failure on laudanosine excretion in man. British Journal of Anaesthesia 57: 1049–1051, 1985
Fahey MR, Rupp SM, Fisher DM, Miller RD, Sharma M. et al. The pharmacokinetics and pharmacodynamics of atracurium in patients with and without renal failure. Anesthesiology 61: 699–702, 1984
Hull CJ. A model for atracurium?. British Journal of Anaesthesia 55: 95–96, 1983
Hunter JM, Jones RS, Utting JE. Comparison of vecuronium, atracurium and tubocurarine in normal patients and in patients with no renal function. British Journal of Anaesthesia 56: 941–950, 1984
Mercier J, Mercier E. Action de quelques alcaloides secondaires de l’opium sur l’électrocorticogramme du chien. Comptes Rendus des Séances de la Société de Biologie et de ses Filiales 149: 760–762, 1955
Neill EAM, Chapple DJ. Metabolic studies in the cat with atracurium: a neuromuscular blocking agent designed for non enzymic inactivation at physiological pH. Xenobiotica 12: 203–210, 1982
Nguyen HD, Kaplan R, Nagashima H, Duncalf D, Foldes FF. The neuromuscular effect of atracurium in anephric patients. Abstract. Anesthesiology 63: A335, 1985
Nigrovic V, Gallup W, Pandya J, Fry K. Generation of reactive metabolites during spontaneous degradation of atracurium in vitro. American Journal of Medical Sciences 296: 12–17, 1989
Nigrovic V, Pandya JB. Reactivity and toxicity of atracurium and its metabolites in vitro. Canadian Journal of Anaesthesia 36: 262–268, 1989
Nigrovic V, Smith S. Involvement of nucleophiles in the inactivation of atracurium. British Journal of Anaesthesia 59: 617–621, 1987
Parker CJP, Jones JE, Hunter JM. Disposition of infusions of atracurium and its metabolite, laudanosine, in patients in renal and respiratory failure in an ITU. British Journal of Anaesthesia 61: 531–540, 1988
Pong SF, Graham LT. A relatively simple differential screening test for GABA or glycine antagonists using rat electroretinography. Archives Internationales de Pharmacodynamie et de Thérapie 220: 275–286, 1976
Scaf AHJ. Pharmacokinetic analyses with RUGF1T: an interactive pharmacokinetic computer program. Biopharmaceutics and Drue Disposition 9: 415–446, 1988
Stenlake JB, Waigh RD, Dewar GH, Dhar NC, Hughes R. et al. Biodegradable neuromuscular blocking agents. Stereochemical studies on atracurium and related polyalkylene di-esters. European Journal of Medical Chemistry 19: 441–450, 1984
Stenlake JB, Waigh RD, Urwin J, Dewar GH, Coker GG. Atracurium: conception and inception. British Journal of Anaesthesia 55: 3S–10S, 1983
Tsui D, Graham DD, Torda TA. The pharmacokinetics of atracurium isomers in vitro and in humans. Anesthesiology 67: 722–728, 1987
Uges DRA, Bloemhof H, Agoston S. The determination of atracurium and its metabolite laudanosine in serum by HPLC. Abstract. Pharmaceutisch Weekblad-Scientific Edition 6: 265, 1984
Ward S, Boheimer N, Weatherley BC, Simmonds RJ, Dopson TA. Pharmacokinetics of atracurium and its metabolites in patients with normal renal function, and in patients in renal failure. British Journal of Anaesthesia 59: 697–706, 1987
Ward S, Neill EAM. Pharmacokinetics of atracurium in acute hepatic failure (with acute renal failure). British Journal of Anaesthesia 55: 1169–1172, 1983
Ward S, Weatherley BC. Pharmacokinetics of atracurium and its metabolites. British Journal of Anaesthesia 58: 6s–10s, 1986
Ward S, Wright D. Combined pharmacokinetic and pharmacodynamic study of a single bolus dose of atracurium. British Journal of Anaesthesia 55: 35S–38S, 1983
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Vandenbrom, R.H.G., Wierda, J.M.K.H. & Agoston, S. Pharmacokinetics and Neuromuscular Blocking Effects of Atracurium Besylate and Two of Its Metabolites in Patients with Normal and Impaired Renal Function. Clin Pharmacokinet 19, 230–240 (1990). https://doi.org/10.2165/00003088-199019030-00006
Published:
Issue Date:
DOI: https://doi.org/10.2165/00003088-199019030-00006